Pulmatrix Inc (PULM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.71M
Last updated: Nov 17, 2026 at 10:46 AM ET
Performance (10Y)
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 11.6% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 40.4, in the neutral range between 30 and 70.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about PULM
News
PULM Profitability: Margins, ROIC and FCF
Pulmatrix (PULM) has an operating margin of 0.0% and a net margin of 0.0%.
- Operating margin
- 0.0%
- Net margin
- 0.0%
- ROE
- -98.4%
Pulmatrix Competitors
The companies most similar to Pulmatrix (PULM) include Processa Pharmaceuticals, Liminatus Pharma, Inc. Class A Common Stock and Aprea Therapeutics.
Sector: Healthcare
Companies most similar to PulmatrixPULM Bull Case vs Bear Case
Bull case
- PULM beat EPS estimates in 75.0% of its last 8 reported quarters.
Bear case
- PULM's quarterly revenue changed -99.9% year over year.
PULM Earnings: Beat Rate
Pulmatrix (PULM) beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate (75.0%). Its next report is expected on Feb 24, 2027.
- Beat rate
- 6 of 8 quarters (75.0%)
- Average surprise
- 11.9%
PULM Earnings Date
PULM reports Feb 24, 2027. The date is estimated.
Updated Nov 16, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About PULM
When does PULM report earnings?
Pulmatrix Inc (PULM) is expected to report earnings on Feb 24, 2027.
Does PULM pay dividends?
Pulmatrix Inc (PULM) does not currently pay a regular dividend.
What is PULM's market cap?
Pulmatrix Inc (PULM) has a market capitalization of $4.71M with a current stock price of $1.29.
PULM pages: Overview, Earnings, Financials, Competitors
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.